ABS Bio Acquires Cureline, Broadening Access to Biospecimens & Streamlining Execution From End to End

Blitzer, Clancy & Company represented Cureline, a leading provider of specimen procurement and histology services to the pharmaceutical and life sciences industries.

3 Boomerang Capital Announces Strategic Growth Investment in Analytical Biological Services Inc.

Blitzer, Clancy & Company advised ABS, a leading provider of biopharma biomaterial services.

Unispace Group strengthens its life sciences offering by joining forces with Bulb

Blitzer, Clancy & Company advised London-based Unispace on the deal.

Flagship’s acquisition of ManagedLab

Blitzer, Clancy & Company served as the M&A advisor to Flagship.

Flagship’s acquisition of Biotechnical Services

Blitzer, Clancy & Company served as the M&A advisor to Flagship.

Malema Engineering Corporation’s sale to Dover

Blitzer, Clancy & Company served as sell-side advisor to Malema Engineering.

Unispace’s acquisition of BioPharma Engineering

Blitzer, Clancy & Company advised Unispace in the acquisition of the Ireland-based firm.

Flagship Facility Services’ partnership with DENS

Blitzer, Clancy & Company advised Flagship Facility Services on the deal.

OrthoSensor’s new venture in Glasgow, Scotland

Blitzer, Clancy & Company advised the U.S.-based medtech firm.

C&W Services’ acquisition of the controlled environments practice of Pacific Maintenance Company

Blitzer, Clancy & Company advised C&W Services, a subsidiary of Cushman & Wakefield.

AMETEK’s acquisition of Amptek Inc.

Blitzer, Clancy & Company advised Berwyn, Pennsylvania-based AMETEK Inc. on the deal.

AMETEK’s acquisition of Luphos GmbH

Blitzer, Clancy & Company advised Berwyn, Pennsylvania-based AMETEK Inc. on the deal.